India Pharma Outlook Team | Tuesday, 28 October 2025
India released a list of registered interested parties on Monday, advancing an anti-dumping inquiry into imports of ethambutol hydrochloride, an active pharmaceutical ingredient used in anti-tuberculosis medications, from China and Thailand.
Following a plea by domestic pharmaceutical company Lupin Ltd. alleging that imports were being dumped at unreasonably cheap prices, harming Indian producers, the Directorate General of Trade Remedies (DGTR) opened the probe last month.
The inquiry coincides with India's increased attempts to combat unfair trade practices that hurt homegrown businesses. In September, the trade remedies authority released 15 final conclusions on such practices in a variety of industries, from steel and glass fiber to chemical products and solar cells.
Also Read: Zydus Gets Health Canada Nod for Mesalamine Suppository
On Monday, the DGTR indicated Lupin Ltd as the participant from the domestic industry and Wuhan Wuyao Pharmaceuticals Co. Ltd of China amongst the foreign respondents.
The DGTR stated that they had found evidence of both dumping and injury, with products imported at prices lower than domestic prices.
The investigation will cover the period from April 2024 to March 2025 and if it is determined that there was injury to the Indian industry then anti-dumping duties may be applied.
In September, the DGTR commenced 13 additional anti-dumping and countervailing investigations, primarily covering imports from China and South Korea.
.jpg)
